Pacific Edge Limited (ASX:PEB)

Market Cap	72.94M
Revenue (ttm)	20.67M
Net Income (ttm)	-27.20M
Shares Out	n/a
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,573
Average Volume	10,594
Open	0.0850
Previous Close	0.0910
Day's Range	0.0850 - 0.0970
52-Week Range	0.0500 - 0.1800
Beta	1.01
RSI	59.18
Earnings Date	May 23, 2025

About Pacific Edge

Pacific Edge Limited, a cancer diagnostics company, engages in development and commercialization of bladder cancer diagnostic and prognostic tests for patients. It operates through two segments, Commercial and Research. The company offers Cxbladder, a genomic urine biomarker test for the detection and surveillance of bladder cancer. It also develops Cxbladder Triage, a frontline diagnostic product that helps de-intensify clinical work-up for patients with haematuria who have a low probability of bladder cancer; and Cxbladder Monitor, a non-inva...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2001
• Employees: 114
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: PEB

Financial Performance

In 2024, Pacific Edge's revenue was 24.67 million, a decrease of -2.20% compared to the previous year's 25.23 million. Losses were -29.94 million, 1.36% more than in 2023.

Financial numbers in NZD